Marinus Pharmaceuticals Inc
(NASDAQ : MRNS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
1.40%18.8414.1%$236.26m
SHPGShire PLC Sponsored ADR
-0.96%125.460.4%$194.02m
SAGESAGE Therapeutics, Inc.
3.72%169.259.8%$117.83m
PRGOPerrigo Co. Plc
0.92%87.846.6%$82.57m
ICPTIntercept Pharmaceuticals, Inc.
-1.32%59.9822.0%$70.11m
MDCOMedicines Company
2.90%33.7522.1%$64.70m
JAZZJazz Pharmaceuticals Plc
0.97%146.192.2%$57.04m
MNKMallinckrodt Plc
-0.09%16.7018.5%$52.98m
GWPHGW Pharmaceuticals PLC Sponsored ADR
3.01%134.777.6%$51.36m
CTLTCatalent Inc
1.77%43.232.6%$51.26m
UTHRUnited Therapeutics Corporation
-7.72%124.5414.5%$48.46m
ICLRICON Plc
-0.35%114.664.1%$43.72m
PBHPrestige Brands Holdings, Inc.
0.14%34.923.8%$41.47m
CORTCorcept Therapeutics Incorporated.
3.58%15.905.5%$40.23m
PTLAPortola Pharmaceuticals, Inc.
-6.31%45.187.8%$37.88m

Company Profile

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of neuropsychiatric therapeutics. Its clinical stage drug candidate, ganaxolone, is a novel synthetic small molecule that is an analog of allopregnanolone, a natural occurring neurosteriod produced by the human body, which modulates gamma-aminobutyric acid a neurotransmitter in the brain. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.